BTIG analyst Ryan Zimmerman assigned a Buy rating to Organogenesis Holdings (ORGO – Research Report) today and set a price target of $4.00. The company’s shares closed yesterday at $2.34.
According to TipRanks, Zimmerman is a 4-star analyst with an average return of 7.8% and a 43.61% success rate. Zimmerman covers the Healthcare sector, focusing on stocks such as Stryker, Zimmer Biomet Holdings, and Glaukos.
Currently, the analyst consensus on Organogenesis Holdings is a Moderate Buy with an average price target of $3.50.
See Insiders’ Hot Stocks on TipRanks >>
Based on Organogenesis Holdings’ latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $117.32 million and a net profit of $5.32 million. In comparison, last year the company earned a revenue of $121.4 million and had a net profit of $8.74 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Organogenesis Holdings, Inc. is a regenerative medical company. It focuses on the development, manufacture and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company was founded in 1985 and is headquartered in Canton, MA.
Read More on ORGO:
- Organogenesis Holdings Inc. to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference
- Organogenesis slides after reporting Q2 results, removing FY guidance
- Organogenesis price target lowered to $4 from $10 at BTIG
- Organogenesis Holdings Inc. Reports Second Quarter 2023 Financial Results; Withdraws Fiscal Year 2023 Guidance
- ORGO Earnings Report this Week: Is It a Buy, Ahead of Earnings?
